SELUMETINIB inhibits MEK1/2, a mitogen-activated protein kinase, which can abrogate resistance, leading to improved antitumor efficacy in renal cell carcinoma [54]. The gene discussed is WNK2; the disease is hereditary clear cell renal cell carcinoma.